Company intelligence / Profile preview
OncoLab
Goyang-si, Gyeonggi-do, South Koreaoncolab.co.kr ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
OncoLab’s lead program using the ANGel platform achieved approximately 50% complete remission in preclinical models of triple-negative breast cancer. The company is preparing for GLP-compliant toxicology studies and IND-enabling activities, with clinical translation targeted after 2025.
- Therapeutic areas
- Oncology
- Modalities
- AntibodyPeptidesSmall moleculeAntibody-drug conjugateBispecific monoclonal antibody
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Currently seeking global co-development partnerships; no major pharma partners publicly disclosed as of June 2025.
Beyond the preview
Go deeper on OncoLab.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OncoLab.